Protective Efficacy of Inhaled BCG Vaccination Against Ultra-Low Dose Aerosol

BCG T-cell memory aerosol vaccination immunogenicity macaque non-human primate tuberculosis vaccine

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
25 Apr 2020
Historique:
received: 07 04 2020
revised: 21 04 2020
accepted: 22 04 2020
entrez: 30 4 2020
pubmed: 30 4 2020
medline: 30 4 2020
Statut: epublish

Résumé

Ten million cases of tuberculosis (TB) were reported in 2018 with a further 1.5 million deaths attributed to the disease. Improved vaccination strategies are urgently required to tackle the ongoing global TB epidemic. In the absence of a validated correlate of protection, highly characterised pre-clinical models are required to assess the protective efficacy of new vaccination strategies. In this study, we demonstrate the application of a rhesus macaque ultra-low dose (ULD) aerosol

Identifiants

pubmed: 32344890
pii: pharmaceutics12050394
doi: 10.3390/pharmaceutics12050394
pmc: PMC7284565
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

JAMA. 1994 Mar 2;271(9):698-702
pubmed: 8309034
J Immunol. 2016 Aug 15;197(4):1100-1110
pubmed: 27412415
Infect Immun. 2015 Mar;83(3):852-62
pubmed: 25547788
PLoS One. 2017 Mar 8;12(3):e0171906
pubmed: 28273087
J Comp Pathol. 2013 Nov;149(4):475-85
pubmed: 23880551
Biomed Res Int. 2017;2017:5089752
pubmed: 28512637
Infect Immun. 2003 Oct;71(10):5831-44
pubmed: 14500505
Lancet. 2006 Apr 8;367(9517):1173-80
pubmed: 16616560
J Clin Invest. 2006 Jun;116(6):1514-24
pubmed: 16691294
Infect Immun. 2004 Feb;72(2):1065-71
pubmed: 14742554
Mol Med. 2012 May 09;18:647-58
pubmed: 22396020
Nat Med. 2011 Sep 18;17(10):1290-7
pubmed: 21926977
Int J Tuberc Lung Dis. 2001 Jul;5(7):664-72
pubmed: 11467373
Tuberculosis (Edinb). 2009 Nov;89(6):405-16
pubmed: 19879805
J Aerosol Med Pulm Drug Deliv. 2014 Oct;27(5):341-8
pubmed: 25105472
Cytometry A. 2011 Feb;79(2):167-74
pubmed: 21265010
J Comp Pathol. 2015 Feb-Apr;152(2-3):217-26
pubmed: 25481611
J Appl Microbiol. 2011 Aug;111(2):350-9
pubmed: 21651681
Proc Jpn Acad Ser B Phys Biol Sci. 2011;87(8):463-85
pubmed: 21986312
Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4656-60
pubmed: 18344320
Clin Vaccine Immunol. 2015 Sep;22(9):992-1003
pubmed: 26108288
J Pharmacol Toxicol Methods. 2004 Jan-Feb;49(1):39-55
pubmed: 14670693
Tuberculosis (Edinb). 2017 May;104:46-57
pubmed: 28454649
Tuberculosis (Edinb). 2016 Jan;96:1-12
pubmed: 26786648
J Immunol. 2002 Jan 1;168(1):29-43
pubmed: 11751943
Int J Tuberc Lung Dis. 1998 Mar;2(3):200-7
pubmed: 9526191
Nat Rev Immunol. 2008 Apr;8(4):247-58
pubmed: 18323851
J Immunol. 2013 Jun 15;190(12):6320-8
pubmed: 23690470
Tuberculosis (Edinb). 2016 Dec;101:174-190
pubmed: 27865390
Nature. 2020 Jan;577(7788):95-102
pubmed: 31894150
J Hyg (Lond). 1969 Sep;67(3):437-48
pubmed: 5258223
Expert Rev Mol Diagn. 2012 Mar;12(2):175-87
pubmed: 22369377
N Engl J Med. 2018 Jul 12;379(2):138-149
pubmed: 29996082
Int J Immunopharmacol. 1994 May-Jun;16(5-6):435-44
pubmed: 7927990
Infect Immun. 2018 Jan 22;86(2):
pubmed: 29203540
Adv Drug Deliv Rev. 2014 Aug;75:3-17
pubmed: 24732364
Am Rev Respir Dis. 1973 Mar;107(3):351-8
pubmed: 4632221
Expert Rev Vaccines. 2019 Dec;18(12):1271-1284
pubmed: 31876199
Clin Vaccine Immunol. 2010 Aug;17(8):1170-82
pubmed: 20534795
Curr Drug Deliv. 2008 Apr;5(2):114-9
pubmed: 18393813
Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11497-502
pubmed: 11562492

Auteurs

Andrew D White (AD)

Public Health England, National Infection Service, Porton Down, Salisbury SP4 0JG, UK.

Charlotte Sarfas (C)

Public Health England, National Infection Service, Porton Down, Salisbury SP4 0JG, UK.

Laura S Sibley (LS)

Public Health England, National Infection Service, Porton Down, Salisbury SP4 0JG, UK.

Jennie Gullick (J)

Public Health England, National Infection Service, Porton Down, Salisbury SP4 0JG, UK.

Simon Clark (S)

Public Health England, National Infection Service, Porton Down, Salisbury SP4 0JG, UK.

Emma Rayner (E)

Public Health England, National Infection Service, Porton Down, Salisbury SP4 0JG, UK.

Fergus Gleeson (F)

The Churchill Hospital, Headington, Oxford OX3 7LE, UK.

Martí Català (M)

Comparative Medicine and Bioimage Centre of Catalonia (CMCiB), Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, 08916 Catalonia, Spain.

Isabel Nogueira (I)

Servei de Radiodiagnòstic, Hospital Universitari Germans Trias i Pujol, Badalona, 08916 Catalonia, Spain.

Pere-Joan Cardona (PJ)

Unitat de Tuberculosi Experimental, Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Universitat Autònoma de Barcelona, CIBERES, 28029 Madrid, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES). Av. Monforte de Lemos, 3-5. Pabellón 11. Planta 0. 28029 Madrid, Spain.

Cristina Vilaplana (C)

Unitat de Tuberculosi Experimental, Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Universitat Autònoma de Barcelona, CIBERES, 28029 Madrid, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES). Av. Monforte de Lemos, 3-5. Pabellón 11. Planta 0. 28029 Madrid, Spain.

Mike J Dennis (MJ)

Public Health England, National Infection Service, Porton Down, Salisbury SP4 0JG, UK.

Ann Williams (A)

Public Health England, National Infection Service, Porton Down, Salisbury SP4 0JG, UK.

Sally A Sharpe (SA)

Public Health England, National Infection Service, Porton Down, Salisbury SP4 0JG, UK.

Classifications MeSH